Overview
ACRS market data
Price History
ACRS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.53 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -921.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.58 – $6.52 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $886.9M · P/B 3.16 · P/S 107.91.
Company News
8-K filing — Aclaris Therapeutics, Inc. (ACRS)SEC EDGAR · Aug 6, 2026, 9:15 PM
Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026Benzinga · Aug 6, 2026, 8:37 PM
Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M EstimateBenzinga · Aug 6, 2026, 11:00 AM
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Jun 22, 2026, 12:05 PM